{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"13.6","value":"7.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Ixabepilone"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 5 years of follow-up.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}